This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.63% per year. These returns cover a period from January 1, 1988 through December 2, 2019. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Exelixis' Cabometyx Gets FDA Nod for First-Line Kidney Cancer
by Zacks Equity Research
Exelixis (EXEL) received a significant boost with the approval of label expansion of lead drug Cabometyx for first-line kidney cancer.
Endo (ENDP) Earnings & Revenues Beat in Q3, Generics Weak
by Zacks Equity Research
Endo (ENDP) announced better-than-expected results for the third quarter. However, weakness in the generics segment persist and will impact results.
Perrigo (PRGO) Q3 Earnings Top, 2017 View Raised, Shares Up
by Zacks Equity Research
Perrigo (PRGO) posts better-than-expected earnings with revenues also beating estimates. The company ups its guidance, courtesy of a continued positive execution across all business segments.
Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up
by Zacks Equity Research
Merrimack (MACK) reported narrower-than-expected loss in the third quarter. With no marketed product after Onivyde sale, the company is now focused on developing its pipeline candidates.
Pacira (PCRX) Posts Earnings in Q3, Revenues Lag Estimates
by Zacks Equity Research
Pacira's (PCRX) earnings surpassed estimates but sales missed the same in the third quarter of 2017. The company remains focused on the label expansion of Exparel.
Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Catalyst Pharma (CPRX) remains focused on the development of its pipeline candidate firdapse in the third quarter of 2017.
VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down
by Zacks Equity Research
VIVUS (VVUS) reported third-quarter results wherein it reported narrower-than- expected loss. However, Qsymia sales fell from the year-ago period.
Aerie (AERI) Q3 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
Increased operating expenses mar Aerie's (AERI) Q3 performance.
Jazz Pharmaceuticals (JAZZ) Q3 Earnings Top, 2017 View Cut
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) earnings beat estimates while revenues miss the same in Q3. The company also cuts its guidance due to lower-than-expected sales from Xyrem.
Regeneron (REGN) Beats on Q3 Earnings & Sales, Shares Up
by Zacks Equity Research
Regeneron reported impressive results in the third quarter driven by strong performance of Eylea.
Agenus (AGEN) Reports In Line Loss in Q3, Revenues Lag
by Zacks Equity Research
Agenus (AGEN) incurred in line loss but sales missed estimates in the third quarter of 2017.
Infinity (INFI) Q3 Loss Narrower than Expected, View Intact
by Zacks Equity Research
Infinity Pharmaceuticals (INFI) Q3 loss was narrower than estimates and the year-ago quarter loss.
AVEO Pharmaceuticals Q3 Loss Narrows, Focus on Fotivda
by Zacks Equity Research
AVEO Pharmaceuticals reported narrower-than-expected adjusted loss in the third quarter. Moreover, it received approval for its first drug, Fotivda, which was approved in EU for bladder cancer.
Arena Pharmaceuticals (ARNA) Q3 Loss Widens Y/Y, Sales Beat
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) reports another quarter of lackluster Belviq sales. However, the company is likely to advance ralinepag in phase III study based on positive data from the previous stage.
Spectrum (SPPI) Earnings, Sales Beat Q3 Estimates
by Zacks Equity Research
Spectrum (SPPI) reports narrower-than-expected loss in Q3. Shares up.
Achillion (ACHN) Q3 Loss Narrows, Pipeline Expansion in Focus
by Zacks Equity Research
Achillion Pharmaceuticals' (ACHN) third-quarter loss was narrower than estimates. The company is focusing on expanding its key pipeline candidate in several indications.
Radius Health (RDUS) Earnings Miss in Q3, Tymlos in Focus
by Zacks Equity Research
Radius Health (RDUS) reported a wider-than-expected loss in third-quarter as expenses grew significantly for the commercialization of Tymlos.
Agios (AGIO) Q3 Loss Narrower than Expected, Revenues Up Y/Y
by Zacks Equity Research
Agios (AGIO) reports narrower-than-expected loss with revenues marginally beating estimates. The top line also improves year over year, thanks to reimbursement received from Celgene.
Zoetis (ZTS) Beats on Q3 Earnings & Sales, Ups 2017 View
by Zacks Equity Research
Zoetis (ZTS) reported impressive third-quarter results beating estimates on both counts. Revenues were driven by strong demand for companion animal products worldwide.
Geron (GERN) Q3 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Geron's (GERN) loss per share in the third quarter was narrower than expected. However, revenues missed estimates. Imetelstat remains in focus.
Exelixis (EXEL) Beats Q3 Earnings on Solid Cabometyx Sales
by Zacks Equity Research
Exelixis (EXEL) beat both earnings and sales estimates in the third quarter fueled by strong demand for Cabometyx for RCC.
Conatus (CNAT) Loss Wider Than Expected in Q3, Sales Miss
by Zacks Equity Research
Conatus (CNAT) reports wider-than-expected loss in Q3. However, revenues significantly increased year over year.
Sucampo (SCMP) Beats on Q3 Earnings & Revenues, Ups '17 View
by Zacks Equity Research
Sucampo Pharmaceuticals' (SCMP) Amitizia recorded strong sales in the United States and Japan, which drove the company's top line in Q3. The company is also working on expanding its Amitizia's label.
Intercept (ICPT) Q3 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Intercept's (ICPT) third-quarter results were encouraging as loss was narrower than expected while Ocaliva registered a sequential increase.
Acorda (ACOR) Q3 Earnings Lag Estimates, Revenues Up Y/Y
by Zacks Equity Research
Acorda's (ACOR) performance in Q3 misses earnings and revenue estimates. However, the company's key drug Ampyra witnessed increase in sales year over year and inched up sequentially.